Search

Displaying results 4601 - 4610 of 9333 in total
  1. Drug

    Lefradafiban

    go.drugbank.com/drugs/DB04863
    Investigational

    Lefradafiban is an oral platelet glycoprotein IIb/IIIa receptor antagonist being investigated in the treatment of angina.

  2. Drug

    Amrubicin

    go.drugbank.com/drugs/DB06263
    Investigational

    Amrubicin is a third-generation synthetic anthracycline currently in development for the treatment of small cell lung cancer. Pharmion licensed the rights to Amrubicin in November 2006. … Since January 2005, Amrubicin has been marketed by Nippon Kayaku, a Japanese pharmaceutical firm focused on oncology, which licensed Japanese marketing rights from Dainippon Sumitomo, the original developer

  3. Drug

    Cediranib

    go.drugbank.com/drugs/DB04849
    Investigational

    It is being developed clinically as a once-daily oral therapy for the treatment of cancer. … The novel indole-ether quinazoline Cediranib is a highly potent (IC<sub>50</sub> &lt; 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro.

  4. Drug

    Trichloroacetate

    go.drugbank.com/drugs/DB11152
    ApprovedInvestigational

    Trichloroacetate, or trichloroacetic acid, is a strong acid prepared by the reaction of chlorine with acetic acid in the presence of a suitable catalyst. … Trichloroacetate is also found in cosmetic treatments and topical formulations as a cauterant, which removes condyloma or warts on the skin.

  5. Drug

    ACE393

    go.drugbank.com/drugs/DB05071
    Investigational

    ACE393 is an injectable vaccine designed to combat the bacterium Campylobacter jejuni, one of the greatest causes of bacterial diarrhoeal infections in the developed world.

  6. Drug

    Trapidil

    go.drugbank.com/drugs/DB09283
    Experimental

    Trapidil, a platelet-derived growth factor antagonist, was originally developed as a vasodilator and anti-platelet agent and has been used to treat patients with ischemic coronary heart, liver, and kidney

  7. Drug

    Mebendazole

    go.drugbank.com/drugs/DB00643
    ApprovedInvestigationalVet approved

    A benzimidazole that acts by interfering with carbohydrate metabolism and inhibiting polymerization of microtubules. [PubChem]

    International brands: Mopen
  8. Drug

    SYNB1020

    go.drugbank.com/drugs/DB17667
    Investigational

    It was initially designed to convert ammonia to L-arginine [A258838] and granted orphan designation by the FDA for the treatment of urea cycle disorders in August 2016;[L45988] however, the manufacturer … discontinued further development of SYNB1020 to treat hyperammonemia due to a lack of evidence of ammonia-lowering activities by SYNB1020 in a Phase 1b/2a study.

  9. Drug

    LY-517717

    go.drugbank.com/drugs/DB05713
    Investigational

    It is believed to be Lilly's PMD-3112 (licensed from Amgen).

  10. Drug

    Neuropeptide Y

    go.drugbank.com/drugs/DB11788
    ApprovedInvestigationalWithdrawn

    Neuropeptide Y is under investigation for the basic science of Type 2 Diabetes Mellitus.